
<style>
    * {
        box-sizing: border-box !important;
    }

    body {
        font-family: 'Inter', 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif !important;
        line-height: 1.9 !important;
        color: #1f1f1f !important;
        max-width: none !important;
        margin: 0 !important;
        padding: 8px 16px 16px 16px !important;
        background: #ffffff !important;
        font-size: 16.5px !important;
    }

    p {
        margin-bottom: 20px !important;
        font-size: 16.5px !important;
        line-height: 1.95 !important;
        color: #1f1f1f !important;
        font-weight: 400 !important;
    }

    strong, b {
        color: #1a73e8 !important;
        font-weight: 700 !important;
        background: rgba(26, 115, 232, 0.08) !important;
        padding: 2px 6px !important;
        border-radius: 8px !important;
    }

    /* Details/Summary (collapsible sections) */
    details {
        background: linear-gradient(135deg, #f8f9fa 0%, #ffffff 100%) !important;
        border-radius: 8px !important;
        padding: 24px 28px !important;
        margin: 24px 0 !important;
        border: none;
        box-shadow: none !important;
        transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1) !important;
    }

    details:hover {
        border-color: #1a73e8 !important;
        box-shadow: none !important;
        transform: translateY(-2px) !important;
    }

    details[open] {
        background: #ffffff !important;
        border-color: #1a73e8 !important;
        box-shadow: none !important;
    }

    summary {
        cursor: pointer !important;
        font-weight: 800 !important;
        color: #ffffff !important;
        font-size: 20px !important;
        padding: 16px 24px !important;
        border-radius: 8px !important;
        background: linear-gradient(135deg, #1a73e8 0%, #1557b0 100%) !important;
        transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1) !important;
        display: flex !important;
        align-items: center !important;
        user-select: none !important;
        box-shadow: none !important;
        letter-spacing: 0.5px !important;
    }

    summary:hover {
        background: linear-gradient(135deg, #1557b0 0%, #0d47a1 100%) !important;
        transform: translateX(6px) scale(1.02) !important;
        box-shadow: none !important;
    }

    summary:active {
        transform: translateX(4px) scale(0.99) !important;
    }

    summary::marker {
        color: rgba(255, 255, 255, 0.9) !important;
        font-size: 1.3em !important;
    }

    summary strong {
        background: rgba(255, 255, 255, 0.2) !important;
        color: #ffffff !important;
        padding: 4px 12px !important;
        border-radius: 8px !important;
        margin-left: 8px !important;
        font-size: 19px !important;
        letter-spacing: 1px !important;
    }

    /* Tables - Premium Design */
    table {
        width: 100% !important;
        border-collapse: separate !important;
        border-spacing: 0 !important;
        margin: 28px 0 !important;
        border-radius: 8px !important;
        overflow: hidden !important;
        box-shadow: none !important;
        border: none !important;
        background: #ffffff !important;
    }

    table.simple-table {
        background: linear-gradient(135deg, #ffffff 0%, #f8f9fa 100%) !important;
    }

    table tr {
        transition: all 0.25s cubic-bezier(0.4, 0, 0.2, 1) !important;
        position: relative !important;
    }

    table tr:nth-child(odd) {
        background: rgba(248, 249, 250, 0.5) !important;
    }

    table tr:nth-child(even) {
        background: rgba(255, 255, 255, 0.8) !important;
    }

    table tr:hover {
        background: linear-gradient(90deg, #e8f0fe 0%, #f1f8ff 100%) !important;
        transform: translateX(4px) scale(1.01) !important;
        box-shadow: none !important;
        z-index: 1 !important;
    }

    table td {
        padding: 18px 24px !important;
        border-bottom: 1px solid rgba(232, 234, 237, 0.6) !important;
        font-size: 16.5px !important;
        line-height: 1.7 !important;
        color: #1f1f1f !important;
        vertical-align: middle !important;
    }

    table tr:last-child td {
        border-bottom: none !important;
    }

    /* First column (A, B, C, D, E) */
    table td:first-child {
        font-weight: 800 !important;
        color: #ffffff !important;
        width: 52px !important;
        text-align: center !important;
        font-size: 18px !important;
        background: linear-gradient(135deg, #1a73e8 0%, #1557b0 100%) !important;
        border-right: 3px solid #1557b0 !important;
        position: relative !important;
        letter-spacing: 0.5px !important;
    }

    table tr:hover td:first-child {
        background: linear-gradient(135deg, #1557b0 0%, #0d47a1 100%) !important;
        box-shadow: none !important;
    }

    /* Second column (content) */
    table td:nth-child(2) {
        font-weight: 500 !important;
        padding-left: 28px !important;
    }

    /* Third column (empty - hide it) */
    table td:last-child:empty {
        display: none !important;
    }

    /* Lists */
    ul, ol {
        margin: 16px 0 !important;
        padding-left: 32px !important;
    }

    li {
        margin: 10px 0 !important;
        line-height: 1.8 !important;
        color: #1f1f1f !important;
    }

    ul.bulleted-list li {
        position: relative !important;
        padding-left: 8px !important;
    }

    ul.toggle {
        list-style: none !important;
        padding-left: 0 !important;
    }

    /* Links */
    a {
        color: #1a73e8 !important;
        text-decoration: none !important;
        font-weight: 600 !important;
        border-bottom: 2px solid transparent !important;
        transition: all 0.2s !important;
    }

    a:hover {
        border-bottom-color: #1a73e8 !important;
        background: rgba(26,115,232,0.08) !important;
        padding: 2px 4px !important;
        border-radius: 8px !important;
    }

    /* Images & Media */
    img, video {
        max-width: none !important;
        height: auto !important;
        border-radius: 8px !important;
        box-shadow: none !important;
        margin: 24px 0 !important;
        display: block !important;
        border: none !important;
    }

    img:hover, video:hover {
        box-shadow: none !important;
        border-color: #1a73e8 !important;
    }

    /* Code blocks (if any) */
    code {
        background: #f1f3f4 !important;
        padding: 2px 8px !important;
        border-radius: 8px !important;
        font-family: 'Courier New', monospace !important;
        font-size: 14px !important;
        color: #d93025 !important;
    }

    pre {
        background: #f8f9fa !important;
        padding: 8px 16px 16px 16px !important;
        border-radius: 8px !important;
        overflow-x: auto !important;
        border-left: 4px solid #1a73e8 !important;
    }

    /* Headings */
    h1, h2, h3, h4, h5, h6 {
        color: #1a73e8 !important;
        font-weight: 700 !important;
        margin-top: 24px !important;
        margin-bottom: 16px !important;
        line-height: 1.4 !important;
    }

    h1 { font-size: 32px !important; }
    h2 { font-size: 26px !important; }
    h3 { font-size: 22px !important; }
    h4 { font-size: 19px !important; }

    /* Blockquotes */
    blockquote {
        border-left: 4px solid #1a73e8 !important;
        padding-left: 20px !important;
        margin: 20px 0 !important;
        font-style: italic !important;
        color: #5f6368 !important;
        background: #f8f9fa !important;
        padding: 16px 20px !important;
        border-radius: 8px !important;
    }

    /* Horizontal Rule */
    hr {
        border: none !important;
        height: 2px !important;
        background: linear-gradient(to right, transparent, #1a73e8, transparent) !important;
        margin: 32px 0 !important;
    }

    /* Selection */
    ::selection {
        background: #e8f0fe !important;
        color: #1a73e8 !important;
    }

    /* Highlighter styles */
    .highlighted {
        background-color: #ffeb3b !important;
        transition: background-color 0.2s ease !important;
    }

    .highlighter-btn {
        background: none !important;
        border: none !important;
        cursor: pointer !important;
        font-size: 20px !important;
        padding: 0 8px !important;
        margin-left: 8px !important;
        transition: transform 0.2s ease !important;
        vertical-align: middle !important;
    }

    .highlighter-btn:hover {
        transform: scale(1.2) !important;
    }

    .highlighter-btn.active {
        transform: scale(1.1) !important;
        filter: brightness(1.2) !important;
    }

    .highlighter-mode-active {
        cursor: text !important;
    }


    /* Right padding to avoid overlap with sidebar buttons */
    body {
        padding-right: 50px !important;
    }

    @media (max-width: 768px) {
        body {
            padding-right: 16px !important;
        }
    }

</style>




<details open>
<summary><strong>19391</strong><button class="bionic-reading-btn" onclick="toggleBionicReading(event)" title="Toggle Bionic Reading (Ctrl+B)"><span id="bionicIcon">üëÅÔ∏è</span></button><button class="highlighter-btn" onclick="toggleHighlighter(event)" title="Toggle Highlighter (Ctrl+H)"><span id="highlighterIcon">üñäÔ∏è</span></button></summary>
<p class="" id="0d662a2c-c151-4e2c-b8e7-fdb48543475c">As part of the Food and Drug
                                        Administration drug approval process, a study is conducted to assess the
                                        clinical benefit and toxicity of a new drug that is intended to be used in
                                        combination with current standard chemotherapy for patients with recurrent
                                        glioblastoma.  Fifty patients with recurrent glioblastoma enroll in the trial
                                        and are randomized to receive standard chemotherapy plus either placebo or 1 of
                                        3 possible doses of the new drug.  Study results show a dose-dependent reduction
                                        in tumor size with all 3 doses of the new drug, along with a significant
                                        increase in adverse drug effects, including hypertension, muscle weakness,
                                        lymphopenia, and hypophosphatemia.  The researchers conclude that the middle
                                        dose of the new drug offers the greatest ratio of benefit to toxicity.  Which of
                                        the following best describes this type of study?</p>
<table class="simple-table" id="a234fb46-0e15-40d3-8439-137e0c0a3eb0">
<tbody>
<tr id="c9aab07c-69fb-4b40-81bc-d91864b79d67">
<td class="" id="`@ZC">A.</td>
<td class="" id=":@Il">Phase I clinical trial</td>
<td class="" id="]UFi"></td>
</tr>
<tr id="85fe9414-ce3e-4efc-8676-506b06e39928">
<td class="" id="`@ZC">B.</td>
<td class="" id=":@Il">Phase II clinical trial</td>
<td class="" id="]UFi"></td>
</tr>
<tr id="fe710127-f9ee-4f91-b812-15bc9dbe740b">
<td class="" id="`@ZC">C.</td>
<td class="" id=":@Il">Phase III clinical trial</td>
<td class="" id="]UFi"></td>
</tr>
<tr id="dea751d5-1d47-472f-adfa-bb5b451e4e01">
<td class="" id="`@ZC">D.</td>
<td class="" id=":@Il">Phase IV clinical trial</td>
<td class="" id="]UFi"></td>
</tr>
<tr id="dfe21ba1-e7a1-4fd7-9f87-dd1b7bcd4fc4">
<td class="" id="`@ZC">E.</td>
<td class="" id=":@Il">Preclinical study</td>
<td class="" id="]UFi"></td>
</tr>
</tbody>
</table>
<ul class="toggle" id="8a760b35-b02b-4f5c-ab43-5bba3bd04e6c">
<li>
<details>
<summary>Submit</summary>
<table class="simple-table" id="f0dfc0c1-9cca-4857-8097-602a9ea1f035">
<tbody>
<tr id="3402f2fb-4161-4f0a-9e1f-deff66fb63e7">
<td class="" id="Kx[X">A.</td>
<td class="" id="@SEt">Phase I clinical trial (12%)</td>
<td class="" id="f?es"></td>
</tr>
<tr id="0741dd03-3df5-4aa2-9cda-910a666e39eb">
<td class="" id="Kx[X">B.</td>
<td class="" id="@SEt">Phase II clinical trial (47%)</td>
<td class="" id="f?es"></td>
</tr>
<tr id="8fa28ed7-98c8-43b8-b843-e608ad03dabf">
<td class="" id="Kx[X">C.</td>
<td class="" id="@SEt">Phase III clinical trial (31%)</td>
<td class="" id="f?es"></td>
</tr>
<tr id="d0d69e7b-37a8-43c0-b5f6-1d8a6a477301">
<td class="" id="Kx[X">D.</td>
<td class="" id="@SEt">Phase IV clinical trial (7%)</td>
<td class="" id="f?es"></td>
</tr>
<tr id="7fced575-3bea-4164-b848-c22dfb6152ee">
<td class="" id="Kx[X">E.</td>
<td class="" id="@SEt">Preclinical study (0%)</td>
<td class="" id="f?es"></td>
</tr>
</tbody>
</table>
<p class="" id="78c56578-8800-46bc-ba8e-76e177166ec5">Incorrect</p>
<p class="" id="e28b9e19-02b7-4ccf-935d-30c8bbc65ad9">Correct answer B
                                                </p>
<p class="" id="b6bf7830-9a13-405e-9ac7-43bffcf03ce0">47%Answered
                                                    correctly</p>
<p class="" id="a020f079-fe90-4f06-af78-928362dc37e6">14 secsTime Spent
                                                </p>
<p class="" id="89a35139-19cc-4b83-a88a-c1006afb67b5">2024Version</p>
<ul class="bulleted-list" id="ab6db505-1718-4b02-b789-5d96d21e5d39">
<li style="list-style-type:disc">Explanation</li>
</ul>
<ul class="bulleted-list" id="bdfd6710-b5c5-4f26-b750-512c4c675c00">
<li style="list-style-type:disc"></li>
</ul>
<figure class="image" id="a3a2d67e-b846-45c9-8266-287f6d15edab"><a href="https://lh7-us.googleusercontent.com/jAeWWcC1px2BjLLKCD8ai7NTnco2CeJYsgvJ6fFZGkyTCpn4HreAWv1BRXskUQ_wGKEWT4FZmKytJhkap6-KiyaY56rmVhwOh4Ch7fTOIjEZL1z9dKFOVWuwXpm9GPQF_9KIcN_g8vu5-Pm4DFgt4UE"><img loading="lazy" src="https://lh7-us.googleusercontent.com/jAeWWcC1px2BjLLKCD8ai7NTnco2CeJYsgvJ6fFZGkyTCpn4HreAWv1BRXskUQ_wGKEWT4FZmKytJhkap6-KiyaY56rmVhwOh4Ch7fTOIjEZL1z9dKFOVWuwXpm9GPQF_9KIcN_g8vu5-Pm4DFgt4UE" style="width:602px"/></a>
</figure>
<p class="" id="745a4129-0ea7-4e43-95e1-4a9b21043114">Efficacy and
                                                    safety of new drugs are established during the clinical trials
                                                    process.  New drugs are approved by a regulatory body (eg, Food and
                                                    Drug Administration) following review of phase I to III trials. 
                                                    Phases differ in size, objective, and participant selection.</p>
<ul class="bulleted-list" id="33ab2892-0430-45a2-9616-be6a8a046982">
<li style="list-style-type:disc">Phase I: small trials usually
                                                        conducted with healthy participants to assess safety and
                                                        pharmacokinetics, often performed in a strictly controlled
                                                        environment with extensive biochemical and physiologic
                                                        monitoring. Although some phase I chemotherapy trials may
                                                        involve subjects with cancer due to the inherent toxicity of
                                                        treatment, drug efficacy (eg, tumor size reduction) is not
                                                        assessed during a phase I trial (Choice A).</li>
</ul>
<ul class="bulleted-list" id="408cdfc8-ad54-477e-b961-d0842d4b3b5c">
<li style="list-style-type:disc">Phase II: small- to medium-sized
                                                        trials conducted with participants having the condition of
                                                        interest to assess treatment efficacy, toxicity, adverse
                                                        effects, and optimal dosing strategies. These studies may or may
                                                        not have a control group and can be called pilot studies.</li>
</ul>
<ul class="bulleted-list" id="3992e434-8f04-4e95-a659-64b1d33badc5">
<li style="list-style-type:disc">Phase III: large trials (typically
                                                        &gt;300 patients) that are adequately powered to fully assess
                                                        treatment response and safety, often including analysis of
                                                        treatment effects in selected subsets of the target patient
                                                        population. These trials must show adequate effectiveness and
                                                        safety compared to standard treatment for the drug to obtain
                                                        regulatory approval.</li>
</ul>
<p class="" id="560c4806-0773-4f4c-ba41-2829a0d6fddd">(Choice C)  This
                                                    trial enrolled a small number of participants with recurrent
                                                    glioblastoma and compared multiple drug doses with respect to
                                                    treatment efficacy and toxicity.  The results were reported to
                                                    advise optimal drug dosing (ie, dose-finding); although drug dose
                                                    correlated with a decrease in tumor size, effectiveness and safety
                                                    outcomes were not compared with the standard treatment (eg,
                                                    absolute/relative risks).  Therefore, this study is best
                                                    characterized as a phase II trial.</p>
<p class="" id="e4f8b26e-d66f-4d7c-a0eb-99ee24995c02">(Choice D)  Phase
                                                    IV trials are performed after a new drug has obtained regulatory
                                                    approval for clinical use.  These trials are typically performed to
                                                    assess long-term benefits and risks or identify uncommon adverse
                                                    effects that were not fully characterized in phase III studies.</p>
<p class="" id="2a2971cb-c73f-4480-acd3-ce6d3c49d08f">(Choice E)  In
                                                    contrast to phase I, II, III, and IV trials, which include human
                                                    subjects, preclinical studies do not involve human subjects.</p>
<p class="" id="b2e1ba86-95b0-40b5-a6fa-32728fac366c">Educational
                                                    objective:</p>
<p class="" id="e2b2aeff-13c8-4af0-b050-bca2b030acf0">Phase II studies
                                                    are small- to medium-sized trials conducted with participants having
                                                    the condition of interest to assess treatment efficacy, toxicity,
                                                    adverse effects, and optimal dosing strategies; they are sometimes
                                                    called pilot studies.</p>
<p class="" id="53d5d30b-3000-4972-a403-674fbdc617c9">References</p>
<ul class="bulleted-list" id="3632d654-506d-4ecc-af80-165f1ee6924d">
<li style="list-style-type:disc"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21904102">Key
                                                            concepts of clinical trials: a narrative review.</a></li>
</ul>
<p class="" id="683d545f-7b56-44a7-abc2-1165eb865650">Biostatistics</p>
<p class="" id="5cff1630-e66f-4059-a0f9-25b063ad7fc6">Subject</p>
<p class="" id="54041c1c-0ac5-44da-99d9-d044fa57beca">Biostatistics
                                                    &amp; Epidemiology</p>
<p class="" id="0d017c21-c20d-49f4-ba51-7a55af1b4191">System</p>
<p class="" id="ab4fa77f-927c-4f47-a356-54c55e84db12">Clinical trials
                                                </p>
<p class="" id="859a62d4-061e-4211-84e3-d16ce92b60be">Topic</p>
<p class="" id="973444dd-870e-4194-9739-2008775eec0c">Copyright ¬©
                                                    UWorld. All rights reserved.</p>
</details>
</li>
</ul>
</details>


















<style>
.bionic-reading-btn {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    width: 40px;
    height: 40px;
    background: rgba(255, 255, 255, 0.2);
    border: 2px solid rgba(255, 255, 255, 0.3);
    border-radius: 8px;
    color: white;
    font-size: 20px;
    cursor: pointer;
    transition: all 0.3s;
    margin-left: auto;
    flex-shrink: 0;
}

.bionic-reading-btn:hover {
    background: rgba(255, 255, 255, 0.35);
    border-color: rgba(255, 255, 255, 0.5);
    transform: scale(1.1);
}

.bionic-reading-btn.active {
    background: rgba(52, 168, 83, 0.4);
    border-color: rgba(52, 168, 83, 0.6);
}

.bionic-reading-btn.active:hover {
    background: rgba(52, 168, 83, 0.5);
}

summary {
    display: flex !important;
    align-items: center !important;
    gap: 12px !important;
}

    /* Highlighter styles */
    .highlighted {
        background-color: #ffeb3b !important;
        transition: background-color 0.2s ease !important;
    }

    .highlighter-btn {
        background: none !important;
        border: none !important;
        cursor: pointer !important;
        font-size: 20px !important;
        padding: 0 8px !important;
        margin-left: 8px !important;
        transition: transform 0.2s ease !important;
        vertical-align: middle !important;
    }

    .highlighter-btn:hover {
        transform: scale(1.2) !important;
    }

    .highlighter-btn.active {
        transform: scale(1.1) !important;
        filter: brightness(1.2) !important;
    }

    .highlighter-mode-active {
        cursor: text !important;
    }


    /* Right padding to avoid overlap with sidebar buttons */
    body {
        padding-right: 50px !important;
    }

    @media (max-width: 768px) {
        body {
            padding-right: 16px !important;
        }
    }

</style>



<script>
let bionicEnabled = false;
const originalContent = {};

function toggleBionicReading(event) {
    if (event) {
        event.preventDefault();
        event.stopPropagation();
    }

    bionicEnabled = !bionicEnabled;
    const btn = document.querySelector('.bionic-reading-btn');
    const icon = document.getElementById('bionicIcon');

    if (bionicEnabled) {
        btn.classList.add('active');
        icon.textContent = '‚úÖ';
        applyBionicReading();
    } else {
        btn.classList.remove('active');
        icon.textContent = 'üëÅÔ∏è';
        restoreOriginalText();
    }
}

function applyBionicReading() {
    // Seleciona todos os elementos de texto, EXCETO summary e buttons
    const textElements = document.querySelectorAll('p:not(summary p):not(button p), td:not(summary td):not(button td), li:not(summary li):not(button li)');

    textElements.forEach((element, index) => {
        // Ignora elementos que cont√™m outros elementos complexos
        if (element.querySelector('p, td, li, h1, h2, h3, h4, h5, h6, button, summary')) {
            return;
        }

        // Ignora se o elemento est√° dentro de um summary ou button
        if (element.closest('summary') || element.closest('button') || element.closest('.bionic-reading-btn')) {
            return;
        }

        // Salva o conte√∫do original
        if (!originalContent[index]) {
            originalContent[index] = {
                element: element,
                html: element.innerHTML
            };
        }

        // Aplica Bionic Reading
        const bionicText = convertToBionic(element.textContent);
        element.innerHTML = bionicText;
    });
}

function restoreOriginalText() {
    // Restaura o conte√∫do original
    Object.values(originalContent).forEach(item => {
        item.element.innerHTML = item.html;
    });
}

function convertToBionic(text) {
    // Divide o texto em palavras, mantendo pontua√ß√£o
    const words = text.split(/(\s+|[.,;:!?()""''\-‚Äì‚Äî])/);

    const bionicWords = words.map(word => {
        // Ignora espa√ßos e pontua√ß√£o
        if (word.match(/^\s+$/) || word.match(/^[.,;:!?()""''\-‚Äì‚Äî]+$/)) {
            return word;
        }

        // Ignora palavras muito curtas (1-2 letras)
        if (word.length <= 2) {
            return word;
        }

        // Determina quantas letras deixar em negrito (metade da palavra, arredondado para cima)
        const boldLength = Math.ceil(word.length / 2);

        // Separa a parte em negrito da parte normal
        const boldPart = word.substring(0, boldLength);
        const normalPart = word.substring(boldLength);

        // Retorna com a primeira parte em negrito
        return `<strong style="font-weight: 700 !important; color: inherit !important; background: none !important; padding: 0 !important;">${boldPart}</strong>${normalPart}`;
    });

    return bionicWords.join('');
}

// Adiciona atalho de teclado (Ctrl+B ou Cmd+B)
document.addEventListener('keydown', function(e) {
    if ((e.ctrlKey || e.metaKey) && e.key === 'b') {
        e.preventDefault();
        toggleBionicReading();
    }
});
</script>

<script>
    let highlighterActive = false;
    let questionHighlights = {};

    // Get question ID from the first summary strong tag
    function getQuestionId() {
        const firstSummary = document.querySelector('summary strong');
        return firstSummary ? firstSummary.textContent.trim() : '1';
    }

    // Load highlights from localStorage
    function loadHighlights() {
        const questionId = getQuestionId();
        const stored = localStorage.getItem('highlights_' + questionId);
        if (stored) {
            questionHighlights = JSON.parse(stored);
            applyStoredHighlights();
        }
    }

    // Save highlights to localStorage
    function saveHighlights() {
        const questionId = getQuestionId();
        localStorage.setItem('highlights_' + questionId, JSON.stringify(questionHighlights));
    }

    // Apply stored highlights
    function applyStoredHighlights() {
        Object.keys(questionHighlights).forEach(key => {
            const element = document.querySelector(`[data-highlight-id="${key}"]`);
            if (element && questionHighlights[key]) {
                element.classList.add('highlighted');
            }
        });
    }

    // Toggle highlighter mode
    function toggleHighlighter(event) {
        event.stopPropagation();
        highlighterActive = !highlighterActive;

        const btn = event.target.closest('.highlighter-btn');
        const icon = btn.querySelector('#highlighterIcon');

        if (highlighterActive) {
            btn.classList.add('active');
            icon.textContent = 'üñçÔ∏è';
            document.body.classList.add('highlighter-mode-active');
        } else {
            btn.classList.remove('active');
            icon.textContent = 'üñäÔ∏è';
            document.body.classList.remove('highlighter-mode-active');
        }
    }

    // Clear all highlights for this question
    function clearHighlights() {
        const questionId = getQuestionId();
        questionHighlights = {};
        localStorage.removeItem('highlights_' + questionId);
        document.querySelectorAll('.highlighted').forEach(el => {
            el.classList.remove('highlighted');
        });
    }

    // Handle text selection and highlighting
    document.addEventListener('mouseup', function(e) {
        if (!highlighterActive) return;

        const selection = window.getSelection();
        if (!selection.toString().trim()) return;

        const range = selection.getRangeAt(0);
        const container = range.commonAncestorContainer;

        // Only highlight text in paragraphs, not in buttons or other elements
        const paragraph = container.nodeType === 3 ? container.parentElement : container;
        if (paragraph.tagName !== 'P' && paragraph.tagName !== 'LI' && paragraph.tagName !== 'TD') {
            return;
        }

        // Create highlight span
        const span = document.createElement('span');
        span.classList.add('highlighted');

        // Generate unique ID for this highlight
        const highlightId = 'hl-' + Date.now() + '-' + Math.random().toString(36).substr(2, 9);
        span.setAttribute('data-highlight-id', highlightId);

        try {
            range.surroundContents(span);
            questionHighlights[highlightId] = true;
            saveHighlights();
        } catch (e) {
            console.log('Could not highlight selection');
        }

        selection.removeAllRanges();
    });

    // Load highlights when page loads
    window.addEventListener('load', loadHighlights);

    // Keyboard shortcut: Ctrl+H to toggle highlighter
    document.addEventListener('keydown', function(e) {
        if (e.ctrlKey && e.key === 'h') {
            e.preventDefault();
            const btn = document.querySelector('.highlighter-btn');
            if (btn) {
                toggleHighlighter({target: btn, stopPropagation: () => {}});
            }
        }
        // Ctrl+Shift+H to clear all highlights
        if (e.ctrlKey && e.shiftKey && e.key === 'H') {
            e.preventDefault();
            if (confirm('Clear all highlights for this question?')) {
                clearHighlights();
            }
        }
    });
</script>
